References
- Simonetti RG, Camma C, Fiorello F, Politi F, D'Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991; 36: 962–72
- Bartlett DL, Carr BI, Marsh JW. Cancer of the Liver. Cancer: Principles & Practice of Oncology, VT DeVita, Jr, S Hellman, SA Rosenberg. Lippincott Williams & Wilkins, Philadelphia 2005; 986–1008
- Ihde DC, Kane RC, Cohen MH, McIntire KR, Minna JD. Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 1977; 61: 1385–7
- Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
- Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 1987; 7: 660–4
- Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13: 346–53
- Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457
- Mann H, Whitney D. On a test whether one or two random variables is stochastically larger than the other. Ann Math Stat 1947; 18: 50–60
- Jonckheere AR. A distribution-free k-sample test against ordered alternatives. Biometrika 1954; 41: 133–45
- Siegel S, Castellan N., Jr. Nonparametric statistics2nd ed. McGraw-Hill, New York 1988
- Halm U, Etzrodt G, Schiefke I, Schmidt F, Witzigmann H, Mossner J, et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 2000; 11: 113–4
- Valle JW, Dangoor A, Beech J, Sherlock DJ, Lee SM, Scarffe JH, et al. Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): Results of a phase II study. Br J Cancer 2005; 92: 628–30
- Thomas MB, Zhu AX. Hepatocellular carcinoma: The need for progress. J Clin Oncol 2005; 23: 2892–9
- Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093–108
- Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657–63
- Schwartz J, Schwartz M, Lehrer D, Coll M, Kinkhabwala M, Sung M, et al. Bevacizumab in hepatocellular carcinoma (HCC) in patients without metastasis and without invasion of the portal vein. J Clin Oncol 2005;23:338a. Abstract 4122.
- Rizell M, Cahlin C, Friman S, Hafstrom L, Lonn L, Olausson M, et al. Impressive regression of primary liver cancer after treatment with sirolimus. Acta Oncol 2005; 44: 496